Updated
Reviewed
Jan. 01, 2020
Appendix B: Panel Roster and Financial Disclosures
Section Review Group
| Member | Financial Disclosure | ||
|---|---|---|---|
| Company | Relationship | ||
| Barakat, Lydia | Yale University School of Medicine | None | N/A |
| Campbell, Thomas* | University of Colorado Denver School of Medicine | Gilead Sciences | Advisory Board, Research Support |
| Janssen | Research Support | ||
| Merck | Advisory Board | ||
| ViiV | Advisory Board, Research Support | ||
| Kitchell, Ellen | University of Texas Southwestern | None | N/A |
| Robbins, Gregory | Massachusetts General Hospital | AIDS Clinical Trial Group (ACTG) | Research Support |
| Biogen | Equity Interest | ||
| Citius Pharmaceuticals | Research Support | ||
| Emergent Biosolutions | Research Support | ||
| Gilead Sciences | Research Support | ||
| Leonard Meron Biosciences | Research Support | ||
| Pfizer | Research Support | ||
| United Healthcare | Equity Interest | ||
| * Group lead Note: Members were asked to disclose all relationships from 12 months prior to the reviewed date. The period of reporting was from January 1, 2019, through January 1, 2020. |
|||
Download Guidelines
- Section OnlyPDF (337.79 KB)
- Full GuidelinePDF (3.78 MB)
- Tables OnlyPDF (481.21 KB)